TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

36 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

30 studies on the map

Oral Intradialytic Amino Acid Supplementation to Vitalize End-stage Kidney Disease Patients on Hemodialysis — The University of Texas Health Science Center at San Antonio, San AntonioGenetic Variation in IgG in Alpha 1 Antitrypsin Deficiency — University of Alabama at Birmingham, BirminghamEffect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD — Washington DC Veterans Affairs Medical Center (688), Washington D.C.PET Imaging Evaluation of [11C]SY08 — MGH, CharlestownThe Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM) — UCSF Airway Clinical Research Center, San FranciscoEvaluation of [¹⁸F]MODAG-009 PET Imaging in Synucleinopathies — Institute for Neurodegenerative Disorders and XingImaging, LLC, New HavenA Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease — Barrow Neurological Institute, PhoenixOpen-label Study to Evaluate Brain α-Synuclein Deposition Using PET and [18F]MK-0947 in Parkinson's Disease — Invicro (dba Perceptive), New HavenMechanism of SGLT2 Inhibition in the Kidney — University of Michigan, Ann ArborConcomitant Renal and Urinary Bladder Allograft Transplantation — Mayo Clinic, RochesterFeasibility Trial of Sodium-GLucose coTransporter 2 INhibitors in Pediatric Chronic KIDney DiSease — Ann & Robert H. Lurie Children's Hospital of Chicago, ChicagoCortical Electrophysiology of Response Inhibition in Parkinson's Disease — Emory University Hospital, AtlantaSubclinical Primary Aldosteronism in Diabetes At-Risk for Kidney Disease — Brigham and Women's Hospital, BostonLongitudinal TSPO PET Imaging With [18F]DPA-714 in PPMI (PPMI DPA-714 PET Imaging) — UAB, BirminghamCompare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators — The University of Tennessee Graduate School of Medicine, KnoxvilleBOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease — Cleveland Clinic, ClevelandTitle: A Multimodal Exercise Program With Gamification for Parkinson Disease (MEP+G) — Equilibrium Physical Therapy, VenturaNoise-augmented Automatic Speech Recognition for Speech Treatment in Parkinson's Disease — Teachers College, Columbia University, New YorkPimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis — Southern Arizona VA Health Care System, Tucson, AZ, TucsonElucidating the Role of Cholinergic Degeneration in Cognitive Fluctuations in Lewy Body Dementia — Virginia Commonwealth University, RichmondMultiple Objective Particle Swarm Optimization Postural Instability Gait Disorder — University of Minnesota, MinneapolisEmpagliflozin Treatment in Kidney Transplant Recipients — Edward Hines Jr. VA Hospital, Hines, IL, HinesPersonalized Real-Time DBS and PD Mechanisms — Cleveland Clinic, ClevelandPioglitazone to Reduce Sympathetic Overactivity in CKD Patients — University of Texas at Arlington, ArlingtonOral Iron in Children With Chronic Kidney Disease — Weill Cornell Medicine / New York Presbyterian Hospital, New YorkFeasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD — University of Tennessee Medical Center, KnoxvilleCharacterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases — Vanderbilt University Medical Center, NashvilleComparing Antipsychotic Medications in LBD Over Time — University Health System, San AntonioSafety of Short-course of NSAIDs in Pediatric Patients With CKD — Children's Hospital Colorado, AuroraA Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease. — University of Alabama at Birmingham - School of Medicine- Site Number : 8400003, Birmingham